Costs associated with refractory asthma comorbidities

Lead Investigator:

Liam Heaney, Queens University Belfast (QUB)

Research Team:

The research team will be made up of a a team from the QUB:

  • Joan Sweeney
  • Christopher Patterson

Status: Active


The Respiratory Effectiveness Group




Short description:

It is often stated that asthma costs are driven by unscheduled healthcare resource utilisation, but the drug costs can significantly outstrip the cost of unscheduled healthcare use.
There is a need to understand the true cost of refractory asthma if future high-cost drugs are to be justified.
Aims: to use a large UK primary care database (the Optimum Patient Care Research Database [OPCRD]) to compare the steroid load in a refractory asthma population to that of (matched) milder asthma patients and non-asthmatic controls. The study will evaluate the comorbidity prevalence (stratified by age) and use those rates to model the true (and comparative) cost of refractory asthma among refractory asthma patients (vs well-controlled asthma patients and non-asthmatic controls), evaluate the prevalence of steroid-induced morbidities (cross-sectional phase)Incidence rate of (new) morbidities (prospective phase)
Combining data from the OPCRD and the BTS Difficult Asthma Registry:
Morbidity rates in refractory asthma patients will be compared.
UK prevalence rates for potential steroid-induced morbidities will be provided.
Cost modelling:
The annual cost associated with the treatment and management of systemic steroid-induced morbidities will be estimated
A model estimating the lifetime cost of morbidity attributable to systemic steroid exposure, will be developed.

Documents and Publications




Final Publications

Additional Material